Trial Profile
A Pivotal Phase III trial of Phaxan, a new formulation of alphaxalone dissolved in sulfobutyl ether beta cyclodextrin, for anaesthesia in patients undergoing hip joint replacement; stage 1, the pilot study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Alfaxalone (Primary) ; Propofol; Sevoflurane
- Indications Anaesthesia
- Focus Adverse reactions
- Acronyms PHAXTIVA
- Sponsors Drawbridge Pharmaceuticals
- 27 Jul 2019 Status changed from recruiting to discontinued.
- 23 Nov 2018 Planned End Date changed from 28 Feb 2019 to 30 Sep 2019.
- 23 Jul 2018 Planned End Date changed from 30 Sep 2018 to 28 Feb 2019.